Denosumab's double duty

Amgen Inc. hopes new positive results from two trials of denosumab will help allay safety concerns raised by FDA about giving the mAb to cancer patients, as well as provide additional evidence of the compound's superior efficacy to standard of care.

Last week, Amgen released data from the last of three Phase III trials to reduce the rate of metastases to the bone in advanced cancer patients, while researchers in a company-sponsored study published data from a Phase II trial to treat giant cell tumor of the bone...